<DOC>
	<DOCNO>NCT01882439</DOCNO>
	<brief_summary>To examine safety efficacy tofacitinib subject active psoriatic arthritis previously inadequate response least one TNF inhibitor either due lack efficacy adverse event .</brief_summary>
	<brief_title>Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response TNF Inhibitors</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Active arthritis screening/baseline indicate &gt; /= 3 tender/painful 3 swollen joint Active plaque psoriasis screen Inadequate efficacy lack toleration previously administer TNF inhibitor Nonplaque form psoriasis ( exception nail psoriasis ) History autoimmune rheumatic disease PsA ; also prior history current , rheumatic inflammatory disease PsA</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>psoriatic arthritis</keyword>
	<keyword>tofacitinib</keyword>
	<keyword>ACR20</keyword>
	<keyword>HAQ-DI</keyword>
	<keyword>TNF inhibitor failure</keyword>
</DOC>